New study has mapped immune responses from one of Australia's first novel coronavirus (COVID-19) patients, showing the body's ability to fight the virus and recover from the infection.
New study report on how the patient's immune system responded to the COVID-19 virus. The findings of the study are published in the journal Nature Medicine. Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) - a joint venture between the University of Melbourne and the Royal Melbourne hospital - were able to test blood samples at four different time points in an otherwise healthy woman in her 40s, who presented with COVID-19 and had mild-to-moderate symptoms requiring hospital admission.
‘Even though COVID-19 is caused by a new virus, in an otherwise healthy person, a healthy immune response across different cell types was linked to clinical recovery.
’
Published today in Nature Medicine is a detailed report of how the patient's immune system responded to the virus. One of the authors on the paper, research fellow Dr. Oanh Nguyen said this was the first time that broad immune responses to COVID-19 have been reported."We looked at the whole breadth of the immune response in this patient using the knowledge we have built over many years of looking at immune responses in patients hospitalized with influenza," Dr. Nguyen said.
"Three days after the patient was admitted, we saw large populations of several immune cells, which are often a tell-tale sign of recovery during seasonal influenza infection, so we predicted that the patient would recover in three days, which is what happened."
The research team was able to do this research so rapidly thanks to SETREP-ID (Sentinel Travellers and Research Preparedness for Emerging Infectious Disease), led by Royal Melbourne Hospital Infectious Diseases Physician Dr. Irani Thevarajan at the Doherty Institute.
SETREP-ID is a platform that enables a broad range of biological sampling to take place in returned travelers in the event of a new and unexpected infectious disease outbreak, which is exactly how COVID-19 started in Australia.
Advertisement
"Already established at a number of Melbourne hospitals, we now plan to roll out SETREP-ID as a national study."
Advertisement
"We showed that even though COVID-19 is caused by a new virus, in an otherwise healthy person, a robust immune response across different cell types was associated with clinical recovery, similar to what we see in influenza," Professor Kedzierska said.
"This is an incredible step forward in understanding what drives the recovery of COVID-19. People can use our methods to understand the immune responses in larger COVID-19 cohorts, and also understand what's lacking in those who have fatal outcomes."
Dr. Thevarajan said that current estimates show more than 80 percent of COVID-19 cases are mild-to-moderate, and understanding the immune response in these mild cases is very important to research.
"We hope to now expand our work nationally and internationally to understand why some people die from COVID-19, and build further knowledge to assist in the rapid response of COVID-19 and future emerging viruses," she said.
Source-Eurekalert